Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2016, Article ID 4054806, 6 pages
http://dx.doi.org/10.1155/2016/4054806
Review Article

Clinical Scenarios for Discordant Anti-Xa

1Internal Medicine, Texas Tech University Health Sciences Center at the Permian Basin, 800 W. 4th Street, Odessa, TX 79763, USA
2Texas Tech University Health Sciences Center School of Pharmacy at Dallas, 5920 Forrest Park Lane, Suite 400, Dallas, TX 75235, USA
3University of the Incarnate Word Feik School of Pharmacy, 4301 Broadway, San Antonio, TX 78209, USA
4Departamento de Biología Celular y Tisular, Facultad de Medicina, UNAM, 04510 México, DF, Mexico
5Servicio de Gastrocirugía, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, 06720 México, DF, Mexico

Received 16 February 2016; Accepted 27 April 2016

Academic Editor: Elvira Grandone

Copyright © 2016 Jesus Vera-Aguilera et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. L. Francis and J. B. Groce III, “Challenges in variation and responsiveness of unfractionated heparin,” Pharmacotherapy, vol. 24, no. 8, pp. 108S–119S, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. V. Ignjatovic, R. Summerhayes, A. Gan et al., “Monitoring Unfractionated Heparin (UFH) therapy: which Anti Factor Xa assay is appropriate?” Thrombosis Research, vol. 120, no. 3, pp. 347–351, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Kitchen, J. Theaker, and F. E. Preston, “Monitoring unfractionated heparin therapy: relationship between eight anti-Xa assays and a protamine titration assay,” Blood Coagulation and Fibrinolysis, vol. 11, no. 2, pp. 137–144, 2000. View at Publisher · View at Google Scholar · View at Scopus
  4. F. H. Wians Jr., “Clinical laboratory tests: which, why, and what do the results mean?” Laboratory Medicine, vol. 40, no. 2, pp. 105–113, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. S. M. Bates and J. I. Weitz, “Coagulation assays,” Circulation, vol. 112, no. 4, pp. e53–e60, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. A. P. Wheeler and T. W. Rice, “Coagulopathy in critically ill patients: part 2-soluble clotting factors and hemostatic testing,” Chest, vol. 137, no. 1, pp. 185–194, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. D. M. Adcock, D. C. Kressin, and R. A. Marlar, “Minimum specimen volume requirements for routine coagulation testing: dependence on citrate concentration,” American Journal of Clinical Pathology, vol. 109, no. 5, pp. 595–599, 1998. View at Publisher · View at Google Scholar · View at Scopus
  8. T. H. Spaet, “Case 20-1979: false prolongation of prothrombin time in polycythemia,” The New England Journal of Medicine, vol. 301, no. 9, p. 503, 1979. View at Google Scholar · View at Scopus
  9. R. Eisman, S. Surrey, B. Ramachandran, E. Schwartz, and M. Poncz, “Structural and functional comparison of the genes for human platelet factor 4 and PF4alt,” Blood, vol. 76, no. 2, pp. 336–344, 1990. View at Google Scholar · View at Scopus
  10. E. T. Yin, S. Wessler, and J. V. Butler, “Plasma heparin: a unique, practical, submicrogram-sensitive assay,” The Journal of Laboratory and Clinical Medicine, vol. 81, no. 2, pp. 298–310, 1973. View at Google Scholar · View at Scopus
  11. A. N. Teien, M. Lie, and U. Abildgaard, “Assay of heparin in plasma using a chromogenic substrate for activated factor X,” Thrombosis Research, vol. 8, no. 3, pp. 413–416, 1976. View at Publisher · View at Google Scholar · View at Scopus
  12. A. N. Teien and M. Lie, “Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III,” Thrombosis Research, vol. 10, no. 3, pp. 399–410, 1977. View at Publisher · View at Google Scholar · View at Scopus
  13. Heparin Monograph Series, 2008, http://www.chromogenix.com/.
  14. Biophen Heparin Technical File, 2006, http://www.aniara.com/pdf/SS-ANIARA-Biophen-Heparin-Tech-File.pdf.
  15. L. P. Bechmann, M. Sichau, M. Wichert, G. Gerken, K. Kröger, and P. Hilgard, “Low-molecular-weight heparin in patients with advanced cirrhosis,” Liver International, vol. 31, no. 1, pp. 75–82, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Fuentes, J. Hall, E. Strapp, D. Putney, S. Gordon-Burroughs, and H. Monsour, “907: anti-Xa monitoring for heparin dosing in patients with liver cirrhosis,” Critical Care Medicine, vol. 40, no. 12, Supplement 1, pp. 1–328, 2012. View at Publisher · View at Google Scholar
  17. B. Boneu, C. Caranobe, and P. Sie, “3 Pharmacokinetics of heparin and low molecular weight heparin,” Bailliere's Clinical Haematology, vol. 3, no. 3, pp. 531–544, 1990. View at Publisher · View at Google Scholar · View at Scopus
  18. W. Lim, F. Dentali, J. W. Eikelboom, and M. A. Crowther, “Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency,” Annals of Internal Medicine, vol. 144, no. 9, pp. 673–684, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. L. T. Busby, A. Weyman, and G. M. Rodgers, “Excessive anticoagulation in patients with mild renal insufficiency receiving long-term therapeutic enoxaparin,” American Journal of Hematology, vol. 67, no. 1, pp. 54–56, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. V. Farooq, J. Hegarty, T. Chandrasekar et al., “Serious adverse incidents with the usage of low molecular weight heparins in patients with Chronic Kidney Disease,” American Journal of Kidney Diseases, vol. 43, no. 3, pp. 531–537, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Hirsh and R. Raschke, “Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy,” Chest, vol. 126, no. 3, supplement, pp. 188S–203S, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. E. N. Deal, J. M. Hollands, J. N. Riney, L. P. Skrupky, J. R. Smith, and R. M. Reichley, “Evaluation of therapeutic anticoagulation with enoxaparin and associated anti-Xa monitoring in patients with morbid obesity: a case series,” Journal of Thrombosis and Thrombolysis, vol. 32, no. 2, pp. 188–194, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Hirsh, K. A. Bauer, M. B. Donati, M. Gould, M. M. Samama, and J. I. Weitz, “Parenteral anticoagulants,” Chest, vol. 133, no. 6, pp. 141S–159S, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. E. A. Nutescu, S. A. Spinler, A. Wittkowsky, and W. E. Dager, “Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings,” Annals of Pharmacotherapy, vol. 43, no. 6, pp. 1064–1083, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. G.-J. Sanderink, A. L. Liboux, N. Jariwala et al., “The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers,” Clinical Pharmacology and Therapeutics, vol. 72, no. 3, pp. 308–318, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. S. A. Spinler, F.-S. Ou, M. T. Roe et al., “Weight-based dosing of enoxaparin in obese patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE initiative,” Pharmacotherapy, vol. 29, no. 6, pp. 631–638, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. E. N. Deal, J. M. Hollands, R. M. Reichley, and S. T. Micek, “Incidence, diagnoses, medication use, and outcomes of patients with Class III obesity at a single academic medical center,” American Journal of Health-System Pharmacy, vol. 67, no. 19, pp. 1589–1590, 2010. View at Publisher · View at Google Scholar
  28. N. S. Fox, S. K. Laughon, S. D. Bender, D. H. Saltzman, and A. Rebarber, “Anti-factor Xa plasma levels in pregnant women receiving low molecular weight heparin thromboprophylaxis,” Obstetrics and Gynecology, vol. 112, no. 4, pp. 884–889, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. American College of Obstetricians and Gynecologists, Thromboembolism in Pregnancy, vol. 19 of ACOG Practice Bulletin, ACOG, Washington, DC, USA, 2000.
  30. C. J. Lockwood, “Inherited thrombophilias in pregnant patients: detection and treatment paradigm,” Obstetrics and Gynecology, vol. 99, no. 2, pp. 333–341, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. V. Sephton, R. G. Farquharson, J. Topping et al., “A longitudinal study of maternal dose response to low molecular weight heparin in pregnancy,” Obstetrics and Gynecology, vol. 101, no. 6, pp. 1307–1311, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. C. Gyamfi, R. Cohen, M. T. Desancho, and S. Gaddipati, “Prophylactic dosing adjustment in pregnancy based upon measurements of anti-factor Xa levels,” Journal of Maternal-Fetal and Neonatal Medicine, vol. 18, no. 5, pp. 329–331, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Hepner and V. Karlaftis, “Antithrombin,” Methods in Molecular Biology, vol. 992, pp. 355–364, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. R. D. Rosenberg, “Actions and interactions of antithrombin and heparin,” The New England Journal of Medicine, vol. 292, no. 3, pp. 146–151, 1975. View at Publisher · View at Google Scholar · View at Scopus
  35. P. C. Cooper, F. Coath, M. E. Daly, and M. Makris, “The phenotypic and genetic assessment of antithrombin deficiency,” International Journal of Laboratory Hematology, vol. 33, no. 3, pp. 227–237, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. P. S. Maclean and R. C. Tait, “Hereditary and acquired antithrombin deficiency: epidemiology, pathogenesis and treatment options,” Drugs, vol. 67, no. 10, pp. 1429–1440, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Messori, F. Vacca, M. Vaiani et al., “Antithrombin III in patients admitted to intensive care units: a multicenter observational study,” Critical Care, vol. 6, no. 5, pp. 447–451, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. C. M. Lehman, J. A. Rettmann, L. W. Wilson, and B. A. Markewitz, “Comparative performance of three anti-factor Xa heparin assays in patients in a medical intensive care unit receiving intravenous, unfractionated heparin,” American Journal of Clinical Pathology, vol. 126, no. 3, pp. 416–421, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Levi, M. Schouten, and T. van der Poll, “Sepsis, coagulation, and antithrombin: old lessons and new insights,” Seminars in Thrombosis and Hemostasis, vol. 34, no. 8, pp. 742–746, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. C. M. Lehman and E. L. Frank, “Laboratory monitoring of heparin therapy: partial thromboplastin time or anti-Xa assay?” Laboratory Medicine, vol. 40, no. 1, pp. 47–51, 2009. View at Publisher · View at Google Scholar · View at Scopus